Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Shacter

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Nature Reviews. Drug Discovery|July 20, 2007
The FDA's assessment of follow-on protein products: a historical perspectiveJanet Woodcock, Joseph Griffin, Rachel Behrman, et al.
Cancer|June 22, 2010
CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancerMauro Antonio Alves Castro, Felipe Dal-Pizzol, Stephanie Zdanov, et al.
PDA Journal of Pharmaceutical Science and Technology|April 21, 2019
PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing ApplicationsStephan Krause, Emanuela Lacana, Joel Welch, et al.
Plos One|August 14, 2013
Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical modelJennifer S Dickey, Yanira Gonzalez, Baikuntha Aryal, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Nature Reviews. Drug Discovery|July 20, 2007
The FDA's assessment of follow-on protein products: a historical perspectiveJanet Woodcock, Joseph Griffin, Rachel Behrman, et al.
Cancer|June 22, 2010
CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancerMauro Antonio Alves Castro, Felipe Dal-Pizzol, Stephanie Zdanov, et al.
PDA Journal of Pharmaceutical Science and Technology|April 21, 2019
PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing ApplicationsStephan Krause, Emanuela Lacana, Joel Welch, et al.
Plos One|August 14, 2013
Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical modelJennifer S Dickey, Yanira Gonzalez, Baikuntha Aryal, et al.
Pageof 3